Evidence map›Paper›PMID 30503624›Full record

ArticleKidney international2019

In the absence of natural killer cell activation donor-specific antibody mediates chronic, but not acute, kidney allograft rejection.

Takafumi Yagisawa, Toshiaki Tanaka, Satoshi Miyairi, Kazunari Tanabe, Nina Dvorina, Wayne M Yokoyama, Anna Valujskikh, William M Baldwin, Robert L Fairchild

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Kidney international, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.

0numbers the graph read from it
0cells of the map it votes in
20citing papers in PubMed
2.3field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

20 citing papers in PubMed, 31 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Article
  5. Can mouse kidney transplant models inform mechanisms of injury and acceptance in clinical kidney transplantation?American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons · 2025
    Review
  6. Article
  7. [Therapeutic response and monitoring of antibody-mediated renal graft rejection].Revista medica del Instituto Mexicano del Seguro Social · 2025
    Article
  8. Article
  9. Review
  10. Review
  11. The Transplant Bellwether: Endothelial Cells in Antibody-Mediated Rejection.Journal of immunology (Baltimore, Md. : 1950) · 2023
    Review
  12. Review
  13. Article
  14. Article
  15. Review
  16. Therapies for Chronic Allograft Rejection.Frontiers in pharmacology · 2021
    Review
  17. Review
  18. Review
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 4 institutions in 2 countries.

Takafumi YagisawaLerner Research Institute, Cleveland Clinic, Cleveland, Ohio, USA; Department of Urology, Tokyo Women's Medical University, Tokyo, Japan.
Toshiaki TanakaLerner Research Institute, Cleveland Clinic, Cleveland, Ohio, USA; Department of Urology, Sapporo Medical University School of Medicine, Sapporo, Japan.
Satoshi MiyairiLerner Research Institute, Cleveland Clinic, Cleveland, Ohio, USA; Department of Urology, Tokyo Women's Medical University, Tokyo, Japan.
Kazunari TanabeDepartment of Urology, Tokyo Women's Medical University, Tokyo, Japan.
Nina DvorinaLerner Research Institute, Cleveland Clinic, Cleveland, Ohio, USA.
Wayne M YokoyamaDivision of Rheumatology, Department of Medicine, Washington University School of Medicine, St. Louis, Missouri, USA.
Anna ValujskikhLerner Research Institute, Cleveland Clinic, Cleveland, Ohio, USA.
William M BaldwinLerner Research Institute, Cleveland Clinic, Cleveland, Ohio, USA.
Robert L FairchildLerner Research Institute, Cleveland Clinic, Cleveland, Ohio, USA. Electronic address: fairchr@ccf.org.
Cleveland Clinic Lerner College of Medicine · USSapporo Medical University · JPTokyo Women's Medical University · JPWashington University in St. Louis · US

Funding

Surgery CoreP01AI087586 · NIAID · CLEVELAND CLINIC LERNER COM-CWRU · PI VALUJSKIKH, ANNA · 2010 to 2019
$17.2M
NIAID NIH HHS P01 AI087586
6 · The paper itself

Abstract

Antibody mediated rejection (ABMR) is a major barrier to long-term kidney graft survival. Dysregulated donor-specific antibody (DSA) responses are induced in CCR5-deficient mice transplanted with complete major histocompatibility complex (MHC)-mismatched kidney allografts, and natural killer (NK) cells play a critical role in graft injury and rejection. We investigated the consequence of high DSA titers on kidney graft outcomes in the presence or absence of NK cell activation within the graft. Equivalent serum DSA titers were induced in CCR5-deficient B6 recipients of complete MHC mismatched A/J allografts and semi-allogeneic (A/J x B6) F1 kidney grafts, peaking by day 14 post-transplant. A/J allografts were rejected between days 16-28, whereas B6 isografts and semi-allogeneic grafts survived past day 65. On day 7 post-transplant, NK cell infiltration into A/J allografts was composed of distinct populations expressing high and low levels of the surface antigen NK1.1, with NK1.1

Indexed as

Acute DiseaseAllograftsAnimalsChronic DiseaseDisease Models, AnimalGraft RejectionGraft SurvivalHumansIsoantibodiesKidneyKidney TransplantationKiller Cells, NaturalLymphocyte ActivationMaleMiceMice, Inbred C57BLCCR5 protein, mouseIsoantibodiesReceptors, CCR5antibody-mediated rejectionkidney allograftNK cells

Identifiers

PMID30503624
PMCPMC6342643
OpenAlexW2902416060

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.